TC BIOPHARM HOLDINGS PLC-ADR (TCBP) Stock Price, Forecast & Analysis
USA - NASDAQ:TCBP - US87807D6085 - ADR
TCBP Key Statistics, Chart & Performance
The current stock price of TCBP is 0.5 USD. In the past month the price decreased by -80%. In the past year, price decreased by -99.79%.
TCBP Latest News, Press Relases and Analysis
TCBP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.85 | 381.38B | ||
| AMGN | AMGEN INC | 13.6 | 159.73B | ||
| GILD | GILEAD SCIENCES INC | 15.02 | 152.62B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.29 | 108.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.95 | 66.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 830.33 | 55.51B | ||
| ARGX | ARGENX SE - ADR | 62 | 51.19B | ||
| INSM | INSMED INC | N/A | 38.63B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.99 | 33.96B | ||
| NTRA | NATERA INC | N/A | 26.96B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.20B | ||
| BIIB | BIOGEN INC | 8.92 | 21.89B |
Related stock screener links
About TCBP
Company Profile
TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company employs 41 full-time employees The company went IPO on 2022-02-23. The firm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - phase IIb/III pivotal trial in treatment of acute myeloid leukemia using its proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product is TCB-008. In addition to unmodified allogenic GD-Ts for treatment of blood cancers, the Company is also developing an expanded platform for TCB-008 use case in anti-fungal, anti-viral and anti-microbial diseases. Its unmodified cell therapy, used in the treatment of acute myeloid leukemia, is supplied under the name OmnImmune. The company is also developing a range of genetically modified CAR-T products for the treatment of solid cancers.
Company Info
TC BIOPHARM HOLDINGS PLC-ADR
Maxim 1, 2 Parklands Way, Holytown
Motherwell GB
Employees: 41
Phone: 441414337557
TC BIOPHARM HOLDINGS PLC-ADR / TCBP FAQ
What does TCBP do?
TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company employs 41 full-time employees The company went IPO on 2022-02-23. The firm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - phase IIb/III pivotal trial in treatment of acute myeloid leukemia using its proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product is TCB-008. In addition to unmodified allogenic GD-Ts for treatment of blood cancers, the Company is also developing an expanded platform for TCB-008 use case in anti-fungal, anti-viral and anti-microbial diseases. Its unmodified cell therapy, used in the treatment of acute myeloid leukemia, is supplied under the name OmnImmune. The company is also developing a range of genetically modified CAR-T products for the treatment of solid cancers.
Can you provide the latest stock price for TC BIOPHARM HOLDINGS PLC-ADR?
The current stock price of TCBP is 0.5 USD. The price decreased by -67.53% in the last trading session.
Does TCBP stock pay dividends?
TCBP does not pay a dividend.
What is the ChartMill technical and fundamental rating of TCBP stock?
TCBP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists TCBP stock?
TCBP stock is listed on the Nasdaq exchange.
Who owns TC BIOPHARM HOLDINGS PLC-ADR?
You can find the ownership structure of TC BIOPHARM HOLDINGS PLC-ADR (TCBP) on the Ownership tab.
TCBP Technical Analysis
TCBP Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to TCBP. TCBP may be in some trouble as it scores bad on both profitability and health.
TCBP Financial Highlights
Over the last trailing twelve months TCBP reported a non-GAAP Earnings per Share(EPS) of -4.21. The EPS decreased by -27216.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -71.77% | ||
| ROE | -293.88% | ||
| Debt/Equity | 1.07 |
TCBP Forecast & Estimates
7 analysts have analysed TCBP and the average price target is 48.96 USD. This implies a price increase of 9692% is expected in the next year compared to the current price of 0.5.
For the next year, analysts expect an EPS growth of 96.52% and a revenue growth -100% for TCBP